“The median thrombus age of DVT patients treated in our centre is 14 days – says Dr Andrew Wigham from Oxford University Hospitals. – We know that traditional treatment options such as thrombolytics and other thrombectomy devices are less effective once thrombus is more organised. When using the ClotTriever System, we are able to treat those patients effectively”.
Along with the benefits of being able to treat the full chronicity of DVT, dr Wigham highlights a single-session treatment, lytic-free approach and minimising the hospital length of stay for patients, as the additional advantages of the ClotTriever system.
“We treat more and more young patients with DVT and the fact that we can offer a lytic-free treatment and eliminate bleeding risks related to thrombolytics, makes a huge difference – says dr Wigham.
Access to the interventional treatment for eligible DVT patients, remains still a challenge due to the lack of awareness, both among referring and treating physicians, of the effective clot removal from the iliac veins. “There are still many patients receiving thrombolysis and although their symptoms are not improving, they don’t get any interventions – says dr Wigham. – Building dedicated DVT pathways is a crucial task to make sure that the patients receive the right treatment.
To learn more about the ClotTriever system, join the INARI Symposium at CIRSE 2023 where Dr Andrew Wigham and other experts will be discussing a lytic-free thrombectomy as the first choice for both DVT and acute PE (FlowTriever) treatment on Sunday 10th September at 1pm (Auditotium 15).
This video was filmed by Inari Medical and is being sponsored for distribution in association with Vascular News, Interventional News, Venous News and CX Vascular. Biba Medical bears no responsibility for the assets used in the production of this video.